Adverum Biotechnologies Reports Major Corporate Changes
| Field | Detail |
|---|---|
| Company | Adverum Biotechnologies, Inc. |
| Form Type | 8-K |
| Filed Date | Dec 9, 2025 |
| Risk Level | high |
| Pages | 9 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.0001, $3.56, $8.91 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, delisting-risk, governance-change
TL;DR
Adverum Biotechnologies is undergoing major corporate shifts, including asset changes and potential delisting.
AI Summary
Adverum Biotechnologies, Inc. filed an 8-K on December 9, 2025, reporting several material events. These include the completion of an acquisition or disposition of assets, a notice of delisting or failure to meet listing standards, material modifications to security holder rights, and changes in control of the registrant. The filing also covers departures and appointments of officers and directors, as well as amendments to its articles of incorporation or bylaws.
Why It Matters
This 8-K filing indicates significant structural and governance changes at Adverum Biotechnologies, potentially impacting its stock listing, asset ownership, and leadership.
Risk Assessment
Risk Level: high — The filing details multiple significant events including potential delisting, changes in control, and modifications to security holder rights, all of which carry substantial risk.
Key Players & Entities
- Adverum Biotechnologies, Inc. (company) — Registrant
- December 9, 2025 (date) — Date of Report
- Avalanche Biotechnologies, Inc. (company) — Former Company Name
FAQ
What specific assets were involved in the completion of an acquisition or disposition?
The filing does not specify the details of the assets acquired or disposed of.
What are the reasons for the notice of delisting or failure to satisfy a continued listing rule?
The filing does not provide specific reasons for the delisting notice.
What are the material modifications to the rights of security holders?
The filing does not detail the specific modifications to security holder rights.
What has caused the change in control of Adverum Biotechnologies, Inc.?
The filing does not specify the event or transaction that led to the change in control.
Are there any new officers or directors appointed, or any departing?
The filing indicates changes in directors or officers, but does not name specific individuals or their roles.
Filing Stats: 2,555 words · 10 min read · ~9 pages · Grade level 13.4 · Accepted 2025-12-09 16:01:20
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (the "Company Common Stock")
- $3.56 — pany Common Stock") in exchange for (i) $3.56 per Share, net to the stockholder in ca
- $8.91 — cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash
Filing Documents
- d96637d8k.htm (8-K) — 50KB
- d96637dex31.htm (EX-3.1) — 6KB
- d96637dex32.htm (EX-3.2) — 55KB
- 0001193125-25-312722.txt ( ) — 246KB
- advm-20251209.xsd (EX-101.SCH) — 3KB
- advm-20251209_lab.xml (EX-101.LAB) — 18KB
- advm-20251209_pre.xml (EX-101.PRE) — 11KB
- d96637d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 2.1* Agreement and Plan of Merger, dated as of October 24, 2025, by and among Eli Lilly and Company, Ridgeway Acquisition Corporation and Adverum Biotechnologies, Inc. (incorporated by reference to Exhibit 2.1 to Adverum Biotechnologies, Inc.'s Current Report on Form 8-K filed with the SEC on October 24, 2025). 3.1** Sixth Amended and Restated Certificate of Incorporation of Adverum Biotechnologies, Inc. 3.2** Second Amended and Restated Bylaws of Adverum Biotechnologies, Inc. 104 The cover page of this report has been formatted in Inline XBRL. * Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or similar attachment to Exhibit 2.1. ** Filed herewith. 4 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADVERUM BIOTECHNOLOGIES, INC. Date: December 9, 2025 By: /s/ Jonathan Haug Jonathan Haug President